Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab

C. A. Egan, M. Brown, J. D. White, K. B. Yancey

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal blistering disease characterized by IgG anti-basement membrane autoantibodies to collagen VII. Since autoantibody formation in EBA patients is thought to be T-cell-dependent, the degree of T cell activation in three patients (all males, ages 33-44 years) was assessed by quantitation of soluble Tac, a fragment of the α-subunit of the high-affinity IL-2 receptor (CD25). Soluble Tac levels in all patients were elevated [highest random values, 2430, 920, and 560 IU/ml (normal range, 112-502)]. Based on such findings, these patients were treated with the humanized murine monoclonal anti-Tac antibody daclizumab (1 rog/kg, 6-12 iv treatments at 2- to 4-week intervals). All patients had a significant, rapid, and persistent decrease in lymphocyte CD25 expression. Though a moderate decrease in lymphocyte expression of 7G7, an IL-2 receptor epitope not bound by daclizumab, was noted, stable levels of CD3 cells and in vitro saturation studies indicated that daclizumab effectively bound CD25 and did not promote clearance of such cells from peripheral blood. There were no complications and no patient developed antibodies against daclizumab. While no apparent clinical benefit was seen in two patients with dermolytic disease, one patient with inflammatory EBA had a favorable response. While on daclizumab, this patient stopped prednisone, significantly reduced dapsone, and improved clinically. Furthermore, his disease flared when treatment was stopped, and resumption of daclizumab again effected improvement within 2 weeks. Daclizumab therapy is safe and well tolerated in EBA patients. It may be effective as a corticosteroid sparing agent in patients with inflammatory EBA.

Original languageEnglish (US)
Pages (from-to)146-151
Number of pages6
JournalClinical Immunology
Volume101
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Epidermolysis Bullosa Acquisita
Therapeutics
Interleukin-2 Receptors
Autoantibodies
daclizumab
Lymphocytes
T-Lymphocytes
Dapsone
Proxy
Prednisone
Basement Membrane
Epitopes
Anti-Idiotypic Antibodies
Blood Cells
Adrenal Cortex Hormones
Reference Values
Collagen

Keywords

  • Autoimmunity
  • Bullous disease
  • Therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. / Egan, C. A.; Brown, M.; White, J. D.; Yancey, K. B.

In: Clinical Immunology, Vol. 101, No. 2, 2001, p. 146-151.

Research output: Contribution to journalArticle

Egan, C. A. ; Brown, M. ; White, J. D. ; Yancey, K. B. / Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. In: Clinical Immunology. 2001 ; Vol. 101, No. 2. pp. 146-151.
@article{f21d52b8b46448caaf2677016d8f0ba0,
title = "Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab",
abstract = "Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal blistering disease characterized by IgG anti-basement membrane autoantibodies to collagen VII. Since autoantibody formation in EBA patients is thought to be T-cell-dependent, the degree of T cell activation in three patients (all males, ages 33-44 years) was assessed by quantitation of soluble Tac, a fragment of the α-subunit of the high-affinity IL-2 receptor (CD25). Soluble Tac levels in all patients were elevated [highest random values, 2430, 920, and 560 IU/ml (normal range, 112-502)]. Based on such findings, these patients were treated with the humanized murine monoclonal anti-Tac antibody daclizumab (1 rog/kg, 6-12 iv treatments at 2- to 4-week intervals). All patients had a significant, rapid, and persistent decrease in lymphocyte CD25 expression. Though a moderate decrease in lymphocyte expression of 7G7, an IL-2 receptor epitope not bound by daclizumab, was noted, stable levels of CD3 cells and in vitro saturation studies indicated that daclizumab effectively bound CD25 and did not promote clearance of such cells from peripheral blood. There were no complications and no patient developed antibodies against daclizumab. While no apparent clinical benefit was seen in two patients with dermolytic disease, one patient with inflammatory EBA had a favorable response. While on daclizumab, this patient stopped prednisone, significantly reduced dapsone, and improved clinically. Furthermore, his disease flared when treatment was stopped, and resumption of daclizumab again effected improvement within 2 weeks. Daclizumab therapy is safe and well tolerated in EBA patients. It may be effective as a corticosteroid sparing agent in patients with inflammatory EBA.",
keywords = "Autoimmunity, Bullous disease, Therapy",
author = "Egan, {C. A.} and M. Brown and White, {J. D.} and Yancey, {K. B.}",
year = "2001",
doi = "10.1006/clim.2001.5113",
language = "English (US)",
volume = "101",
pages = "146--151",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab

AU - Egan, C. A.

AU - Brown, M.

AU - White, J. D.

AU - Yancey, K. B.

PY - 2001

Y1 - 2001

N2 - Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal blistering disease characterized by IgG anti-basement membrane autoantibodies to collagen VII. Since autoantibody formation in EBA patients is thought to be T-cell-dependent, the degree of T cell activation in three patients (all males, ages 33-44 years) was assessed by quantitation of soluble Tac, a fragment of the α-subunit of the high-affinity IL-2 receptor (CD25). Soluble Tac levels in all patients were elevated [highest random values, 2430, 920, and 560 IU/ml (normal range, 112-502)]. Based on such findings, these patients were treated with the humanized murine monoclonal anti-Tac antibody daclizumab (1 rog/kg, 6-12 iv treatments at 2- to 4-week intervals). All patients had a significant, rapid, and persistent decrease in lymphocyte CD25 expression. Though a moderate decrease in lymphocyte expression of 7G7, an IL-2 receptor epitope not bound by daclizumab, was noted, stable levels of CD3 cells and in vitro saturation studies indicated that daclizumab effectively bound CD25 and did not promote clearance of such cells from peripheral blood. There were no complications and no patient developed antibodies against daclizumab. While no apparent clinical benefit was seen in two patients with dermolytic disease, one patient with inflammatory EBA had a favorable response. While on daclizumab, this patient stopped prednisone, significantly reduced dapsone, and improved clinically. Furthermore, his disease flared when treatment was stopped, and resumption of daclizumab again effected improvement within 2 weeks. Daclizumab therapy is safe and well tolerated in EBA patients. It may be effective as a corticosteroid sparing agent in patients with inflammatory EBA.

AB - Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal blistering disease characterized by IgG anti-basement membrane autoantibodies to collagen VII. Since autoantibody formation in EBA patients is thought to be T-cell-dependent, the degree of T cell activation in three patients (all males, ages 33-44 years) was assessed by quantitation of soluble Tac, a fragment of the α-subunit of the high-affinity IL-2 receptor (CD25). Soluble Tac levels in all patients were elevated [highest random values, 2430, 920, and 560 IU/ml (normal range, 112-502)]. Based on such findings, these patients were treated with the humanized murine monoclonal anti-Tac antibody daclizumab (1 rog/kg, 6-12 iv treatments at 2- to 4-week intervals). All patients had a significant, rapid, and persistent decrease in lymphocyte CD25 expression. Though a moderate decrease in lymphocyte expression of 7G7, an IL-2 receptor epitope not bound by daclizumab, was noted, stable levels of CD3 cells and in vitro saturation studies indicated that daclizumab effectively bound CD25 and did not promote clearance of such cells from peripheral blood. There were no complications and no patient developed antibodies against daclizumab. While no apparent clinical benefit was seen in two patients with dermolytic disease, one patient with inflammatory EBA had a favorable response. While on daclizumab, this patient stopped prednisone, significantly reduced dapsone, and improved clinically. Furthermore, his disease flared when treatment was stopped, and resumption of daclizumab again effected improvement within 2 weeks. Daclizumab therapy is safe and well tolerated in EBA patients. It may be effective as a corticosteroid sparing agent in patients with inflammatory EBA.

KW - Autoimmunity

KW - Bullous disease

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0035188422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035188422&partnerID=8YFLogxK

U2 - 10.1006/clim.2001.5113

DO - 10.1006/clim.2001.5113

M3 - Article

C2 - 11683573

AN - SCOPUS:0035188422

VL - 101

SP - 146

EP - 151

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -